Clinical Trials
Finnish 10-year trial finds partial meniscectomy offers no benefit over sham surgery for degenerative meniscus tears
Rapporteret af AI Billede genereret af AI Faktatjekket
A 10-year follow-up of the Finnish Degenerative Meniscal Lesion Study (FIDELITY) found that arthroscopic partial meniscectomy did not improve symptoms or knee function compared with placebo surgery, and patients assigned to the procedure tended to have worse long-term outcomes.
Tenaya Therapeutics, Inc. released a slide deck on May 17, 2026, covering results from its RIDGE-1 Phase Ib/II trial of TN-401 gene therapy. The presentation focuses on treatment for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.
Rapporteret af AI
Intellia Therapeutics presented top-line data from its phase III HALO study in HAE during the Bank of America Global Healthcare Conference on May 12. The results showed substantial clinical benefits for patients with the condition.
Scientists from the Francis Crick Institute and Vividion Therapeutics have developed chemical compounds that prevent the RAS gene from signaling tumor growth via the PI3K pathway. The treatment stopped tumor growth in mice models of lung and breast cancer without causing side effects like hyperglycemia. It is now entering human clinical trials.
Rapporteret af AI
A combination of enzalutamide and hormone therapy has reduced the risk of death by more than 40% in men with recurring prostate cancer, according to a major clinical trial. The study, involving over 1,000 patients worldwide, was led by researchers at Cedars-Sinai and presented at a medical congress in Berlin. Experts describe the findings as a game changer for treating aggressive cases.